Name: National EBS Association (NEBSA) 2014 Annual Meeting
Start: 2014-02-17T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

ITC Litigation & Section 337

Standard Essential Patents

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Principal Edwin Lavergne (DC) will present at the NEBSA 2014 Annual Meeting.

NEBSA 2014 Annual Meeting

National EBS Association

Global Summit 2026

Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments

Court Declines To Lift 30-Month Stay To Prevent Alleged Unfair Competitive Advantage Between Generics

UK High Court Clarifies Scope of SPC Waiver Notification Requirements

Lessons From Recent Pharma & Med Device Federal Circuit Decisions

Biosimilars Litigation and Client Counseling

ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Fourth Edition

Federal Circuit Reverses Injunction That Barred Clinical Trials in Jazz v. Avadel

HHS Sets Most-Favored-Nation Price Targets for Pharmaceuticals

How Trump’s Latest Drug Price EO Could Impact Pharma

Can Clinical Trials Negate Patentability for Pharma Inventions?